생체내 CRO 시장 - 세계 예측(2026-2032년)

The In Vivo CRO Market is projected to grow by USD 9.45 billion at a CAGR of 8.42% by 2032.

In vivo contract research organizations (CROs) support pharmaceutical, biotechnology, medical device, and academic sponsors by conducting animal-based and translational studies that inform safety, efficacy, pharmacokinetics, pharmacodynamics, toxicology, disease biology, and regulatory decision-making. The sector sits at the intersection of drug discovery outsourcing, preclinical development, laboratory animal science, bioanalytical testing, and regulatory science. Demand is shaped by increasingly complex therapeutic modalities, including biologics, cell and gene therapies, oncology immunotherapies, RNA-based medicines, targeted small molecules, vaccines, and advanced delivery systems. Sponsors rely on in vivo CRO partners to access specialized models, validated protocols, compliant facilities, species-specific expertise, and integrated data packages that can support investigational submissions and clinical translation.

The in vivo CRO landscape is also being influenced by global expectations for reproducibility, animal welfare, data integrity, and the 3Rs principles of replacement, reduction, and refinement. Regulatory agencies continue to encourage scientifically justified use of animal models while accepting qualified alternative methods when appropriate, including new approach methodologies where they are validated and fit for purpose. As a result, leading sponsors increasingly seek CROs that can combine fit-for-purpose in vivo models with ex vivo assays, organoids, imaging, biomarkers, digital pathology, and computational approaches. This executive summary examines the strategic forces reshaping the in vivo CRO industry, with emphasis on artificial intelligence, regional dynamics, economic blocs, country-level capabilities, and practical recommendations for industry leaders.

Transformative Shifts Reshaping In Vivo CRO Services

The in vivo CRO industry is undergoing a structural shift from transactional study execution toward integrated translational research partnerships. Sponsors increasingly expect CROs to contribute to model selection, protocol optimization, endpoint strategy, biomarker planning, regulatory documentation, and cross-functional interpretation of results. This shift is driven by the scientific complexity of modern pipelines, the need to de-risk clinical development earlier, and the rising scrutiny of preclinical reproducibility. In oncology, immunology, metabolic disease, neuroscience, rare disease, infectious disease, and inflammatory disorders, sponsors are prioritizing models that better reflect human biology, including patient-derived xenografts, humanized immune system models, genetically engineered models, microbiome-informed models, and orthotopic disease systems.

Another major transformation is the move toward integrated data ecosystems. In vivo CROs are expanding beyond animal study conduct to include longitudinal imaging, telemetry, digital histopathology, multiplex biomarker analysis, omics profiling, and bioinformatics-enabled interpretation. This creates richer datasets and supports earlier identification of efficacy signals, toxicology concerns, dose-response relationships, and mechanism-of-action evidence. At the same time, sponsors are demanding higher operational transparency, real-time study visibility, harmonized quality systems, and audit-ready documentation. These expectations are pushing CROs to invest in electronic lab notebooks, laboratory information management systems, quality management platforms, chain-of-custody controls, and standardized reporting templates aligned with good laboratory practice where required.

Ethical and regulatory pressures are also reshaping service delivery. The global emphasis on the 3Rs has accelerated adoption of refined humane endpoints, improved analgesia and anesthesia protocols, noninvasive imaging, lower-volume sampling techniques, and statistical designs that reduce animal use without weakening scientific validity. In parallel, the modernization of drug development frameworks is encouraging sponsors to integrate in vivo data with new approach methodologies, including organ-on-chip systems, computational toxicology, high-content screening, and in vitro human-relevant assays. CROs that can position animal studies within an evidence-based, multimodal translational strategy are becoming increasingly important to sponsors seeking regulatory confidence and responsible research practices.

Cumulative Impact of Artificial Intelligence on In Vivo CROs

Artificial intelligence is becoming a practical enabler across the in vivo CRO value chain, particularly in study design, image analysis, pathology review, biomarker discovery, animal monitoring, and operational quality control. In preclinical study planning, AI-assisted literature mining and knowledge graphs can help identify relevant animal models, endpoints, dosing regimens, historical control ranges, and translational biomarkers. These tools support more informed protocol design and can reduce the likelihood of underpowered studies, inappropriate endpoints, or poorly matched disease models. When combined with statistical planning and expert review, AI can contribute to better reproducibility and more efficient animal use.

In study execution, AI-enabled video analytics, automated behavior tracking, telemetry interpretation, and digital cage-side monitoring can detect subtle changes in movement, activity, feeding, respiration, or welfare indicators. These capabilities support earlier intervention, refined humane endpoints, and richer phenotypic data. In imaging-heavy studies, machine learning improves quantification of tumor volumes, lesion burden, organ morphology, biodistribution, and longitudinal response patterns. Digital pathology is another high-impact area, where AI can assist with tissue segmentation, lesion detection, cell counting, immunohistochemistry quantification, and prioritization of slides for expert pathologist review. These applications do not replace scientific or veterinary oversight; rather, they strengthen consistency, throughput, traceability, and data granularity.

AI also affects regulatory readiness and data governance. The use of algorithms in regulated or decision-critical settings requires validation, version control, audit trails, bias assessment, explainability, cybersecurity safeguards, and human-in-the-loop oversight. Sponsors evaluating in vivo CRO partners increasingly look for documented data provenance, validated analytical pipelines, model performance metrics, and policies for responsible AI use. The cumulative impact is a more data-intensive in vivo CRO model in which AI helps improve study quality, animal welfare, endpoint precision, and operational efficiency while requiring stronger governance to maintain scientific credibility and regulatory trust.

Key Regional Insights Across the Global In Vivo CRO Ecosystem

Asia-Pacific is becoming increasingly important for in vivo CRO activity due to its expanding biomedical research base, growing clinical and preclinical infrastructure, and strong government support for life sciences in several economies. China, Japan, South Korea, India, Australia, and Singapore contribute distinct capabilities, ranging from oncology and biologics research to vaccine development, toxicology, and translational medicine. The region benefits from a large scientific workforce and increasing investment in advanced animal models, imaging, and bioanalytical platforms, although sponsors must navigate country-specific regulatory requirements, data transfer rules, animal welfare expectations, and quality-system maturity.

Europe is characterized by rigorous animal welfare regulation, strong public research institutions, and advanced capabilities in translational science, toxicology, and regulatory-grade preclinical research. The European framework places significant emphasis on the 3Rs, ethical review, and harmonized scientific standards, making it influential in global in vivo study design. North America remains a central hub for in vivo CRO services because of its deep pharmaceutical and biotechnology ecosystem, mature regulatory environment, extensive academic research networks, and strong demand for GLP and non-GLP preclinical services. The United States anchors much of the region's translational research activity, while Canada adds strengths in immunology, neuroscience, oncology, and academic-industry collaboration. Regulatory expectations from North American agencies continue to influence global standards for safety pharmacology, toxicology, and investigational-enabling packages.

Latin America is developing as a selective destination for biomedical research partnerships, with Brazil and Mexico playing prominent roles due to their life sciences talent, university research systems, and improving research infrastructure. The region offers opportunities in infectious disease, metabolic disorders, vaccines, and comparative medicine, while operational planning must account for import permits, animal facility standards, ethics committee processes, and cross-border sample logistics. Africa presents emerging opportunities in infectious disease, vaccine research, parasitology, neglected tropical diseases, and public health-related translational research. However, in vivo CRO development across the continent remains uneven and depends on investments in laboratory infrastructure, veterinary oversight, biosecurity, ethics review systems, and international collaboration.

The Middle East is gradually expanding life sciences capacity through national health strategies, research universities, specialty hospitals, and biotechnology initiatives, particularly in countries investing in precision medicine, genomics, and clinical research infrastructure. In vivo CRO capabilities are more concentrated and often linked to academic or government-backed research environments. Across all regions, sponsors are prioritizing CRO partners that demonstrate ethical animal research, validated disease models, transparent quality systems, and regulatory-ready documentation.

Key Group Insights Shaping In Vivo CRO Demand and Collaboration

NATO countries overlap substantially with advanced biomedical research networks across North America and Europe, supporting cross-border scientific collaboration, biosecurity standards, and resilient supply chains for critical research infrastructure. The group's relevance to in vivo CRO strategy is closely linked to research security, harmonized quality expectations, and access to mature academic, government, and industry science ecosystems. The G7 continues to represent a major concentration of pharmaceutical innovation, regulatory science, academic research, and advanced preclinical infrastructure. The United States, Canada, Japan, Germany, France, Italy, and the United Kingdom provide mature ecosystems for GLP toxicology, safety pharmacology, disease modeling, biologics testing, and translational biomarker development.

BRICS economies contribute a diverse set of in vivo CRO capabilities. China and India provide large scientific workforces and expanding preclinical infrastructure, Brazil contributes research strengths in infectious disease and public health, Russia has established biomedical research institutions, and South Africa supports research activity linked to infectious disease, vaccines, and comparative medicine. For sponsors, BRICS markets offer access to scientific expertise and regional disease biology, but require careful assessment of quality systems, regulatory alignment, data governance, and logistics.

The European Union exerts significant influence on in vivo CRO practices through harmonized animal welfare requirements, ethics oversight, medicinal product regulation, and emphasis on the 3Rs. EU-based research environments are particularly relevant for sponsors prioritizing regulatory rigor, high documentation standards, and integration of animal data with alternative methods. ASEAN is gaining relevance in the in vivo CRO ecosystem as member states strengthen biomedical research, clinical development, and manufacturing-linked life sciences capabilities. Singapore is a regional leader in translational research infrastructure, while Malaysia, Thailand, Indonesia, Vietnam, and the Philippines are building capacity in academic research, biomedical training, and regulated healthcare innovation. For sponsors, ASEAN offers strategic value when studies require regional disease relevance, scientific collaboration, or access to emerging research networks, though standards and timelines can vary by country.

The GCC is advancing life sciences through national diversification strategies, precision medicine programs, academic medical centers, and investments in biotechnology infrastructure. While large-scale in vivo CRO capacity is still developing compared with more established regions, the bloc's focus on genomics, rare disease, metabolic disease, and healthcare modernization creates opportunities for translational partnerships. Across these groups, the most competitive in vivo CRO environments are those combining regulatory credibility, specialized models, digital data systems, animal welfare excellence, and transparent quality management.

Key Country Insights for In Vivo CRO Strategy

China has rapidly expanded its preclinical research capacity, advanced animal model development, biologics innovation, and translational infrastructure, making it a major location for in vivo CRO services and drug development support. The United States is the most influential country in the in vivo CRO landscape due to its large biotechnology and pharmaceutical pipeline, extensive venture-backed innovation ecosystem, strong academic research base, and mature regulatory expectations for investigational submissions. Japan offers highly advanced biomedical research, strong regulatory science, and deep expertise in pharmacology, regenerative medicine, oncology, and safety evaluation. India is a significant contributor to pharmaceutical research services, toxicology, pharmacology, vaccine development, and cost-efficient scientific operations, with increasing emphasis on quality systems and global regulatory alignment.

Germany is a key hub for pharmacology, toxicology, biotechnology, and medical innovation, with high standards for scientific quality and laboratory compliance. The United Kingdom remains a major center for biomedical discovery, advanced therapeutics, and translational research, supported by strong universities, national research networks, and regulatory expertise. Australia is valued for high-quality research governance, strong animal ethics oversight, translational medicine capabilities, and compatibility with global development programs. France contributes significant strengths in immunology, oncology, neuroscience, and public research institutions, while South Korea has become an important innovation center for biologics, oncology, cell therapy, and preclinical research, supported by advanced technology infrastructure and government-backed life sciences initiatives.

Italy and Spain offer strong academic and hospital-linked research ecosystems and growing biotechnology activity, with capabilities relevant to pharmacology, translational medicine, and disease-model research. Canada complements the North American environment with strengths in oncology, immunology, neuroscience, infectious disease, and collaborative translational research. Russia maintains established scientific institutes and preclinical research capabilities, though international collaboration may be affected by geopolitical, regulatory, and logistics factors. Brazil is Latin America's leading biomedical research contributor, with notable activity in vaccines, infectious disease, tropical medicine, and public health-oriented translational science. Mexico is emerging as a regional partner for life sciences services, supported by proximity to North American sponsors and growing technical capabilities, although regulatory navigation and infrastructure consistency remain important considerations.

Actionable Recommendations for In Vivo CRO Industry Leaders

Industry leaders should prioritize scientific differentiation by investing in validated disease models, humanized systems, longitudinal imaging, digital pathology, biomarker platforms, and integrated pharmacology-toxicology capabilities. Sponsors are increasingly selecting in vivo CRO partners based on translational relevance rather than basic capacity, making model quality, endpoint precision, and interpretive expertise decisive factors. CROs should strengthen multidisciplinary teams that include veterinarians, pathologists, pharmacologists, toxicologists, biostatisticians, bioinformaticians, and regulatory specialists to support more decision-ready study packages.

Operational leaders should embed the 3Rs into every stage of study design and execution. This includes rigorous power calculations, use of historical control data, noninvasive monitoring, refined endpoints, improved welfare scoring, and integration of alternative methods when scientifically justified. Quality leaders should maintain audit-ready systems with clear data provenance, validated methods, controlled documents, secure electronic records, and transparent deviation management. For AI-enabled workflows, organizations should establish governance covering algorithm validation, human oversight, cybersecurity, explainability, and lifecycle monitoring.

Commercial and partnership teams should build region-specific strategies that reflect regulatory expectations, import-export requirements, ethics review timelines, talent availability, and infrastructure maturity. CROs seeking global relevance should harmonize protocols across sites while allowing necessary local adaptations. Sponsors should conduct due diligence not only on facility capacity but also on scientific track record, animal welfare culture, data integrity controls, veterinary oversight, biosafety readiness, and communication practices. The strongest competitive positioning will come from combining ethical research, regulatory credibility, advanced analytics, and measurable improvements in translational decision-making.

Research Methodology for In Vivo CRO Executive Analysis

This executive summary is developed through a secondary-research-led methodology using publicly available and verifiable sources, including regulatory agency guidance, international animal welfare frameworks, peer-reviewed scientific literature, government life sciences policy documents, clinical and preclinical research standards, and recognized industry practices in pharmacology, toxicology, and translational medicine. The analysis emphasizes qualitative evidence and structural market drivers rather than market sizing, market share, or forecasting.

The research approach includes thematic synthesis of in vivo CRO service trends, regional life sciences capabilities, regulatory expectations, technology adoption patterns, and translational research requirements. Sources are assessed for relevance, recency, methodological credibility, and consistency across jurisdictions. Insights are cross-validated by comparing regulatory direction, scientific publication trends, and observed operational practices in preclinical outsourcing. Particular attention is given to the 3Rs, GLP-aligned quality systems, AI governance, digital pathology, biomarker integration, and the growing role of advanced animal models.

Regional, group, and country insights are structured to reflect documented differences in biomedical infrastructure, research governance, regulatory maturity, and scientific specialization. The methodology avoids unsupported claims and excludes proprietary financial assumptions. The resulting analysis is designed to support strategic planning, partner evaluation, service positioning, and risk assessment for stakeholders operating in or engaging with the in vivo CRO ecosystem.

Conclusion: Strategic Direction for the In Vivo CRO Industry

The in vivo CRO industry is evolving into a more specialized, data-rich, and ethically governed segment of the global drug development ecosystem. Sponsors increasingly require partners that can deliver scientifically relevant animal models, integrated biomarker and imaging data, high-quality toxicology and pharmacology execution, and regulatory-ready documentation. Artificial intelligence, digital pathology, automated monitoring, and advanced analytics are enhancing study precision and operational visibility, while also increasing the need for robust validation and governance.

Regional capabilities are diversifying as North America, Europe, and Japan maintain mature regulatory and scientific ecosystems, while Asia-Pacific, Latin America, the Middle East, and Africa expand selected areas of translational research capacity. Economic and geopolitical groups such as NATO, G7, BRICS, the European Union, ASEAN, and GCC influence collaboration patterns, regulatory alignment, infrastructure resilience, and scientific specialization. Across all geographies, success depends on trust, data integrity, animal welfare, model relevance, and the ability to connect preclinical findings to clinical decision-making.

Industry leaders should view in vivo CRO partnerships not merely as outsourced execution but as strategic extensions of translational development. Organizations that align advanced in vivo capabilities with responsible animal use, AI-enabled insight generation, quality discipline, and regulatory awareness will be best positioned to support complex therapeutic pipelines and improve confidence in early development decisions.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. In Vivo CRO Market, by Type

• 7.1. Introduction
• 7.2. Non-Rodent
• 7.3. Rodent

8. In Vivo CRO Market, by Service Type

• 8.1. Introduction
• 8.2. Clinical Services
• 8.3. Consulting & Strategy
• 8.4. Laboratory Services
• 8.5. Preclinical Services
• 8.6. Regulatory Services
• 8.7. Toxicological & Safety Assessment

9. In Vivo CRO Market, by Modality

• 9.1. Introduction
• 9.2. Large Molecules
• 9.3. Small Molecules

10. In Vivo CRO Market, by Indication

• 10.1. Introduction
• 10.2. Cardiovascular Diseases
  • 10.2.1. Coronary Artery Disease
  • 10.2.2. Heart Failure
• 10.3. Infectious Diseases
  • 10.3.1. Bacterial Infections
  • 10.3.2. Viral Infections
• 10.4. Neurological Disorders
  • 10.4.1. Neurodegenerative Disorders
  • 10.4.2. Psychiatric Disorders
• 10.5. Oncology
  • 10.5.1. Hematological Malignancies
  • 10.5.2. Solid Tumors
• 10.6. Respiratory Disorders
  • 10.6.1. Asthma
  • 10.6.2. Chronic Obstructive Pulmonary Disease

11. In Vivo CRO Market, by End User

• 11.1. Introduction
• 11.2. Academic & Research Institutions
• 11.3. Government & Regulatory Organizations
• 11.4. Medical Device Companies
• 11.5. Pharmaceuticals & Biotechnology Companies

12. In Vivo CRO Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. In Vivo CRO Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. In Vivo CRO Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Altogen Labs
• 16.2. Biocytogen Boston Corp.
• 16.3. Cellvax, SAS
• 16.4. Charles River Laboratories International, Inc.
• 16.5. Crown Bioscience, Inc.
• 16.6. Eurofins Scientific SE
• 16.7. Evotec SE
• 16.8. Explicyte
• 16.9. GEMPHARMATECH LLC
• 16.10. ICON Plc
• 16.11. Imavita S.A.S.
• 16.12. IQVIA Holdings Inc.
• 16.13. IVRS AB
• 16.14. JSR Corporation
• 16.15. Labcorp Drug Development PRIVATE LIMITED
• 16.16. Medpace, Inc.
• 16.17. Melior Discovery Inc.
• 16.18. Noble Life Sciences Inc.
• 16.19. Parexel International Corporation
• 16.20. Pharmacology Discovery Services Ltd.
• 16.21. Pharmaron Beijing Co., Ltd.
• 16.22. Pharmatest Services Ltd.
• 16.23. PPD Inc. by Thermo Fisher Scientific, Inc.
• 16.24. PSI CRO AG
• 16.25. Syneos Health Inc.
• 16.26. Syngene International Limited
• 16.27. Taconic Biosciences, Inc.
• 16.28. WuXi AppTec, Inc.
• 16.29. Yecuris Corporation